Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock

by · The Cerbat Gem

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) EVP George Lloyd sold 79,346 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $38.57, for a total value of $3,060,375.22. Following the completion of the sale, the executive vice president owned 30,654 shares of the company’s stock, valued at $1,182,324.78. The trade was a 72.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Royalty Pharma Price Performance

NASDAQ RPRX traded up $0.17 during trading hours on Friday, reaching $38.60. The company’s stock had a trading volume of 5,268,520 shares, compared to its average volume of 4,341,680. Royalty Pharma PLC has a 1 year low of $24.32 and a 1 year high of $41.24. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $22.28 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.02 and a beta of 0.47. The firm’s 50-day moving average price is $38.30 and its 200-day moving average price is $36.70.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. The firm had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. On average, equities research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s payout ratio is 66.67%.

Analysts Set New Price Targets

A number of research firms have issued reports on RPRX. TD Cowen lifted their price objective on Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective for the company. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Finally, Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.60.

View Our Latest Report on Royalty Pharma

Institutional Trading of Royalty Pharma

Hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC raised its holdings in Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 790 shares in the last quarter. USA Financial Formulas bought a new position in shares of Royalty Pharma during the 2nd quarter worth approximately $32,000. Financial Consulate Inc. purchased a new stake in Royalty Pharma during the third quarter valued at approximately $35,000. WPG Advisers LLC acquired a new stake in Royalty Pharma in the first quarter valued at approximately $39,000. Finally, Larson Financial Group LLC grew its holdings in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 306 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Read More